Related Experiment Video

Updated: Jun 17, 2026

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice
07:01

Electrophoretic Delivery of γ-aminobutyric Acid (GABA) into Epileptic Focus Prevents Seizures in Mice

Published on: May 16, 2019

Valproate in children with newly diagnosed idiopathic generalized epilepsy

K D Holland1, S Monahan, D Morita

  • 1Division of Neurology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH 45229, USA. katherine.holland@cchme.org

Acta Neurologica Scandinavica
|January 9, 2010
PubMed

Insights

Valproate monotherapy effectively treats pediatric idiopathic generalized epilepsy (IGE). Most children achieve seizure freedom at modest valproate doses, with over 95% responding below 25 mg/kg/day.

Area of Science:

  • Pediatric Neurology
  • Clinical Pharmacology
  • Epileptology

Background:

  • Idiopathic generalized epilepsy (IGE) is a common epilepsy syndrome in children.
  • Limited data exists on the dose-response relationship of initial antiepileptic drug (AED) monotherapy for IGE in pediatric populations.
  • Valproate is a widely used AED for various epilepsy types.

Purpose of the Study:

  • To determine the therapeutic dose range of valproate monotherapy in children newly diagnosed with IGE.
  • To characterize the dose-response relationship for valproate in achieving seizure freedom in this population.

Main Methods:

  • A cohort of children with newly diagnosed IGE was identified from a New Onset Seizure Clinic.
  • The effect of initial valproate monotherapy and associated doses on seizure freedom was retrospectively analyzed.
  • Data on patient response, dosage, and adverse effects were collected.

Main Results:

  • Out of 84 identified patients, 57% (48 children) achieved seizure freedom with valproate monotherapy.
  • An additional 10 patients became seizure-free but discontinued valproate due to adverse effects.
  • The mean effective dose in seizure-free children was 15.7 mg/kg/day, with over 95% responding below 25 mg/kg/day.

Conclusions:

  • Valproate monotherapy is effective in achieving seizure freedom in approximately half of children with newly diagnosed IGE.
  • Modest doses of valproate are sufficient for therapeutic efficacy in the majority of pediatric IGE patients.
  • These findings provide valuable dose-response information for initiating valproate treatment in children with IGE.
Abstract

More Related Videos

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy10:22

Interictal High Frequency Oscillations Detected with Simultaneous Magnetoencephalography and Electroencephalography as Biomarker of Pediatric Epilepsy

Published on: December 6, 2016

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy09:57

Electromagnetic Source Imaging in Presurgical Evaluation of Children with Drug-Resistant Epilepsy

Published on: September 20, 2024

Related Concept Videos

Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...